No significant treatment effects were found for cladribine in terms of changes in EDSS or SNRS scores. Both doses of cladribine produced and sustained significant reductions in the presence, number, and volume of gadolinium-enhanced T1 brain lesions on MRI, and cladribine 2.1 mg/kg reduced the accumulation of T2 lesion load. Cladribine at doses up to 2.1 mg/kg was generally safe and well tolerated.
Jaume Sastre‐Garriga, Gordon Ingle, Marco Rovaris, N. Téllez, Bas Jasperse, D. R. Altmann, Béatrice Benedetti, Valerie L. Stevenson, Mara Cercignani, Siobhan M Leary, Frederik Barkhof, Bruno Brochet, Vincent Dousset, Massimo Filippi, Xavier Montalbán, Nynke F. Kalkers, Chris H. Polman, Àlex Rovira, David H. Miller, Alan J. Thompson
Discussion(0)
No comments yet. Be the first to comment.